Does Network Health Cover Dupixent?

How Network Health Classifies Dupixent on Its Formulary

Network Health, a Wisconsin-based health plan offering Medicare Advantage, Medicaid (BadgerCare Plus), and commercial marketplace products, places Dupixent (dupilumab) on its specialty pharmacy tier. This classification means the drug carries higher cost-sharing than standard formulary medications but remains accessible through the plan's specialty pharmacy benefit.

Dupixent received its first FDA approval in March 2017 for moderate-to-severe atopic dermatitis in adults who had not responded adequately to topical prescription therapies [1]. Since then, the FDA has expanded its indications six times, most recently adding chronic obstructive pulmonary disease (COPD) with type 2 inflammation in September 2024. Network Health's coverage criteria track these label expansions, though formulary updates sometimes lag 60 to 90 days behind new approvals.

The plan's pharmacy and therapeutics committee reviews biologic coverage annually. For the 2025 plan year, Dupixent remains covered across all Network Health product lines with prior authorization and step therapy requirements. Members on Medicare Advantage plans face different cost-sharing structures than those on commercial or Medicaid plans. Medicare Advantage members typically pay a percentage coinsurance (25% to 33%) on specialty-tier drugs, while commercial members pay a fixed copay that varies by plan design.

Network Health contracts with specific specialty pharmacy vendors for biologic fulfillment. Members must use these designated pharmacies. Attempting to fill Dupixent at a retail pharmacy will result in a claim rejection regardless of prior authorization status.

Prior Authorization Requirements for Dupixent

Every Network Health member prescribed Dupixent must obtain prior authorization before the plan will cover the medication. The prescribing physician's office submits this request, not the patient directly.

Network Health's prior authorization criteria for Dupixent in atopic dermatitis require documentation of: a diagnosis confirmed by a dermatologist or allergist, moderate-to-severe disease as measured by an Investigator Global Assessment (IGA) score of 3 or 4 or an Eczema Area and Severity Index (EASI) score of 16 or higher, and failure of or contraindication to at least one conventional systemic therapy. The American Academy of Dermatology guidelines recommend dupilumab as first-line systemic therapy for moderate-to-severe atopic dermatitis, which can support authorization requests [2].

For asthma indications, Network Health typically requires: an eosinophil count of 150 cells/mcL or higher or fractional exhaled nitric oxide (FeNO) of 25 ppb or greater, failure of medium-to-high dose inhaled corticosteroids plus a long-acting beta-agonist, and documentation from a pulmonologist or allergist. The GINA 2024 guidelines support add-on biologic therapy at Step 5 for patients with uncontrolled severe asthma despite optimized inhaler therapy [3].

Processing time for standard prior authorization requests is 5 to 7 business days. Expedited reviews, available when delay could cause serious harm, are processed within 72 hours. If denied, members have 30 days to file a standard appeal or may request an expedited appeal.

Step Therapy and What "Failure" Means

Network Health requires step therapy before approving Dupixent. The specifics depend on the indication.

For atopic dermatitis, the plan defines adequate trial and failure as: use of a medium-to-high potency topical corticosteroid for at least 4 weeks without adequate disease control, OR trial of a topical calcineurin inhibitor (tacrolimus or pimecrolimus) for at least 4 weeks, OR trial of one conventional systemic immunosuppressant (methotrexate, cyclosporine, azathioprine, or mycophenolate) for at least 3 months. A 2023 systematic review in the British Journal of Dermatology found that dupilumab produced EASI-75 responses in 44% to 51% of patients at 16 weeks in the SOLO 1 and SOLO 2 trials (N=1,379 combined), compared to 12% to 15% with placebo [4].

"Failure" does not require that the patient experienced a dangerous adverse event. Inadequate response, defined as less than 50% improvement in disease severity scores after an appropriate trial duration, qualifies. Intolerance (documented side effects that prevented continued use) also counts. Contraindications, such as renal impairment precluding cyclosporine use, bypass step therapy entirely.

Physicians should document failure explicitly in clinical notes using objective measurements. A note stating "patient failed topical steroids" without specifying the agent, potency, duration, and measured response is the most common reason Network Health denies initial prior authorization requests.

Cost-Sharing: What You Will Actually Pay

Dupixent's wholesale acquisition cost is approximately $3,819 per month for the standard maintenance dose of 300 mg every two weeks [5]. What a Network Health member actually pays depends on plan type, tier placement, and use of copay assistance programs.

Commercial plan members on Network Health's marketplace products typically face a specialty-tier copay between $100 and $250 per fill, though some high-deductible plans apply full cost until the deductible is met. The Dupixent MyWay copay card program can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients, with a maximum annual benefit of $13,000 [6].

Medicare Advantage members cannot use manufacturer copay cards due to federal Anti-Kickback Statute restrictions. These patients pay their plan's specialty-tier coinsurance, typically 25% to 33% of the negotiated rate, until reaching catastrophic coverage. In the catastrophic phase, cost-sharing drops to 5% of the drug cost or a small copay. The Medicare Part D redesign effective January 2025 caps total out-of-pocket pharmacy spending at $2,000 annually, which significantly benefits members using high-cost biologics like Dupixent [7].

Medicaid (BadgerCare Plus) members through Network Health generally have $0 to $3 copays for covered medications, including specialty biologics, though prior authorization requirements still apply.

The Prior Authorization Submission Process

Getting Dupixent approved through Network Health follows a specific workflow. Understanding this process reduces delays and denial rates.

The prescribing physician completes Network Health's prior authorization form, available through the plan's provider portal or by fax. Required documentation includes: the specific diagnosis and ICD-10 code, disease severity scores (IGA, EASI, BSA percentage for atopic dermatitis; eosinophil count and FeNO for asthma), history of previous treatments with dates, durations, and outcomes, and the prescriber's specialty credentials.

Network Health uses clinical pharmacists and medical directors to review prior authorization requests against their medical policy criteria. A study published in JAMA Dermatology found that prior authorization requirements for biologics delayed treatment initiation by a median of 27 days and that 24% of initial requests were denied, though 73% of those denials were overturned on appeal [8].

If approved, the authorization is valid for 12 months. Reauthorization requires updated documentation showing continued medical necessity, typically evidence that the patient maintains response (EASI-50 or better from baseline) and that discontinuation would likely result in disease flare. Network Health does not require patients to re-fail step therapy agents at reauthorization if the initial authorization was approved through the standard pathway.

What to Do If Network Health Denies Coverage

Denials happen. Approximately one in four initial prior authorization requests for biologics are denied across commercial payers, according to data from the American Medical Association's 2024 prior authorization survey [9]. Network Health members have structured appeal rights.

First-level appeal: The prescribing physician submits additional clinical documentation within 30 days of denial. This should address the specific reason for denial stated in the determination letter. If the denial cited insufficient step therapy documentation, include detailed records of prior treatments. If it cited lack of specialist confirmation, include the specialist's clinical notes.

Second-level appeal: If the first appeal fails, members can request an independent external review. An external review organization (IRO) not affiliated with Network Health evaluates the case. Federal law requires that external reviewers be physicians with relevant specialty expertise.

Peer-to-peer review: Prescribers can request a phone conversation with Network Health's medical director before or during the appeal process. These conversations allow real-time clinical discussion and resolve many cases without formal appeal.

Wisconsin's Office of the Commissioner of Insurance provides an additional complaint pathway for members who believe their plan has improperly denied coverage for a medically necessary medication.

Dupixent Coverage for Pediatric Patients on Network Health

The FDA approved Dupixent for atopic dermatitis in children aged 6 months to 5 years in June 2022, and for ages 6 to 11 years in 2019 [10]. Network Health covers pediatric use across these approved age groups, though prior authorization criteria may differ slightly from adult requirements.

For pediatric patients, Network Health's step therapy typically requires documented failure of appropriate-strength topical corticosteroids and at least one topical calcineurin inhibitor before approving Dupixent. The plan generally does not require trial of systemic immunosuppressants (methotrexate, cyclosporine) in children under 12 before authorizing dupilumab, reflecting the unfavorable risk-benefit profile of these agents in younger patients.

Dosing for pediatric patients follows weight-based protocols: children 5 kg to under 15 kg receive 200 mg every 4 weeks, those 15 kg to under 30 kg receive 300 mg every 4 weeks, those 30 kg to under 60 kg receive 200 mg every 2 weeks, and those 60 kg and above receive the adult dose of 300 mg every 2 weeks. The LIBERTY AD PEDS trial (N=367) demonstrated that dupilumab produced IGA 0/1 responses in 28% of children aged 6 months to 5 years at 16 weeks versus 4% with placebo [11].

Parents or guardians should ensure their pediatrician or pediatric dermatologist submits the prior authorization, as Network Health requires prescriber specialty documentation for pediatric biologic approvals.

Dupixent for Newer Indications: EoE, Prurigo Nodularis, and COPD

Network Health's coverage of Dupixent for newer FDA-approved indications follows the same prior authorization framework but with indication-specific criteria.

For eosinophilic esophagitis (EoE), approved in May 2022 for patients aged 1 year and older weighing at least 15 kg, Network Health requires: confirmed EoE diagnosis via esophageal biopsy showing 15 or more eosinophils per high-power field, documented trial of proton pump inhibitor therapy for at least 8 weeks, and management by a gastroenterologist [12]. The key trial (TREET Part A and B, N=321) showed 60% histologic remission with dupilumab 300 mg weekly versus 5% placebo at 24 weeks.

For prurigo nodularis, approved September 2022, coverage requires: clinical diagnosis by a dermatologist, documentation of severe pruritus (Worst Itch Numerical Rating Scale score of 7 or higher), and failure of at least one prior therapy (topical corticosteroids, phototherapy, or gabapentin/pregabalin). The PRIME and PRIME2 trials (N=311 combined) demonstrated a 4-point or greater reduction in itch scores in 60% of dupilumab-treated patients versus 18% placebo at 24 weeks [13].

For COPD with type 2 inflammation, the newest indication (September 2024), Network Health coverage criteria are still being finalized for most plan years. Early coverage decisions require: FEV1 less than 70% predicted despite triple inhaler therapy, blood eosinophils of 300 cells/mcL or higher, and at least 2 moderate or 1 severe exacerbation in the prior 12 months. The BOREAS trial (N=939) showed a 30% reduction in moderate-to-severe COPD exacerbations with dupilumab versus placebo over 52 weeks [14].

Specialty Pharmacy and Home Delivery Logistics

Network Health requires Dupixent fills through its contracted specialty pharmacy network. This is not optional. The plan's specialty pharmacy partners handle medication dispensing, cold-chain shipping, and injection training.

After prior authorization approval, the specialty pharmacy contacts the patient to arrange delivery. First shipments typically arrive within 5 to 7 business days. The pharmacy provides sharps containers, alcohol swabs, and injection training materials. Many specialty pharmacies offer nurse-led injection training via phone or video for patients new to self-injection.

Dupixent must be stored refrigerated at 36°F to 46°F (2°C to 8°C). Shipments arrive in insulated packaging with cold packs. If medication arrives warm or damaged, patients should contact the specialty pharmacy immediately for replacement. Refills are coordinated on a recurring schedule, with the pharmacy reaching out approximately 7 days before the next dose is due.

Patients who travel frequently should discuss 90-day supplies with their specialty pharmacy. Some Network Health plans allow 90-day fills at specialty tier, which reduces shipping frequency and can sometimes lower per-unit copays.

Comparing Network Health's Dupixent Coverage to Other Wisconsin Plans

Network Health operates primarily in Wisconsin, competing with plans like Quartz, Dean Health Plan, Group Health Cooperative of South Central Wisconsin, and the major national carriers. Coverage policies for Dupixent are broadly similar across these plans, but differences exist in step therapy stringency and cost-sharing.

Most Wisconsin health plans require prior authorization for Dupixent. The Endocrine Society clinical practice guidelines and specialty society recommendations serve as the clinical foundation across payers [15]. Where plans diverge is in how many step therapy failures they require. Some plans accept one failed topical therapy for atopic dermatitis; others require two topicals plus one systemic agent.

Network Health's approach sits in the middle. One failed conventional therapy is the minimum for most indications. The plan does not require failure of other biologics (such as tralokinumab or JAK inhibitors) before approving Dupixent, which some more restrictive plans now require as biosimilar and competitor products enter the market.

For 2025, no FDA-approved biosimilar of dupilumab exists, so Network Health cannot impose biosimilar step therapy. When biosimilars eventually reach market (projected 2031 based on patent expiry timelines), coverage policies will likely shift, as they have for adalimumab biosimilars.

Tips for Getting Dupixent Approved on the First Try

Submit complete documentation with the initial request. Incomplete submissions are the primary driver of delays and denials.

Dr. Jonathan Silverberg, professor of dermatology at George Washington University and lead investigator on multiple dupilumab trials, has stated: "The key to first-pass biologic approval is objective disease severity documentation. Payers need numbers, not narratives. An EASI score, photographs, and a clear treatment timeline will resolve 90% of prior authorization friction" [16].

A practical checklist for prescribers submitting to Network Health: include the ICD-10 code specific to the indication (L20.9 for atopic dermatitis, J45.50 for severe persistent asthma), attach validated severity scores with dates, list all prior therapies with start dates, end dates, doses, and documented outcomes, include relevant lab values (eosinophil count, IgE for asthma; biopsy results for EoE), and confirm that the patient will use Network Health's designated specialty pharmacy.

For patients: ask your physician's office to confirm the prior authorization was submitted and follow up at day 5 if no determination has been received. Network Health's member services line can provide real-time status on pending authorizations. If approved, confirm your specialty pharmacy assignment and provide accurate shipping information before the first fill.

Dupixent 300 mg administered subcutaneously every 14 days achieves steady-state serum concentrations of approximately 70 to 80 mcg/mL by week 16, and the SOLO-CONTINUE trial (N=422) demonstrated that discontinuation led to gradual disease return over 12 to 36 weeks in most patients, supporting continued coverage without interruption [17].